Image For Activity Cover
Multimodal Medical Education on Fibrodysplasia Ossificans Progressiva (FOP)
Description
During this Endocrine News podcast episode, expert faculty discuss FOP diagnostic criteria, the patient experience, including patient impacts and characterization of symptoms, and current and emerging treatment options.
Target Audience
The primary audience for this program is endocrinologists who manage care for and/or are consulted for workup of patients with complex bone symptoms and disorders.
Learning Objectives
1. Apply diagnostic criteria for FOP and consider challenges in making timely and accurate diagnoses.

2. Describe symptomology and diverse aspects of disease burden in FOP for patients and caregivers.

3. Assess mechanisms of action as well as safety and efficacy data of new and emerging pharmacotherapies.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty and Disclosures
Eileen Shore, Ph.D.
Cali and Weldon Research Professor in FOP 
University of Pennsylvania

Elisabeth Marelise W. Eekhoff MD, Ph.D.
Internal Medicine, Musculo Skeletal system 
Amsterdam Univercity Medical Centers

Michelle Davies
Executive Director
The International Fibrodysplasia Ossificans Progressiva Association 

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Eileen Shore, Ph.D.: Ipsen, educatonal programs, advisory panel, consultant.

Elisabeth Marelise W. Eekhoff MD, Ph.D.: Amsterdam UMC, research and trials; EU-IMI, (AZ), Ispen, Regeneron, Incyte, Lilly, patient organizations, board and membership; ICC on FOP; Medical Board, IFOPA patient registry; European FOP Consortium; Amsterdamn Rare Bone Disease Expert Center; Amsterdam Bone Center; NVE BoNe; ASBMR commmittee; ERN BOND 95 rare bone disease expertises).

The following faculty reported no relevant financial relationships: Michelle Davies

The following committee member who planned and reviewed content for this activity reported no relevant financial relationships: 

Panagiota Andreopoulou, M.D.

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.

Acknowledgement of Commercial Support:
This educational activity is supported by an educational grant from Ipsen Biopharmaceuticals, Inc.
Summary
Availability: On-Demand
Expires on May 30, 2025
Cost: FREE
Credit Offered:
1 AMA PRA Category 1 Credit
1 ABIM-MOC Point
1 Participation Credit
Contains: 2 Courses
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By